Wow what an ugly headline. This is gonna take some time to sort out with the stock price. Anavex certainly doesn't do a good job of anticipating push back from its rivals. I guess it is the world we live in. Hopefully the drug works for these older Rett patients and they can get some relief upon approval.
The article stated... "More than seven in 10 patients — roughly 72% — who received Anavex's drug improved on the Rett Syndrome Behavioral Questionnaire. Nearly 39% of placebo patients showed a similar improvement."
Looks like a hit piece...the article had incomplete and incorrect statements to fit the headlines. The problem with these headlines is that they cause the damage and when they issue a correction...no one sees them. Very sneaky way of stock manipulation. From Anavex's perspective...could they have issues a PR two weeks back clarifying the situation....along the lines of..."FDA wanted more rigorous and accurate end point" or "It is done as per the original FDA approved plan to make the study....". That would have helped by preparing the ground. Anyway, we shall bounce form this too.
News 
Market Data 
Discover 
